Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial
In this post hoc analysis of the GALACTIC-HF trial, we observed a potential reduction in life-threatening arrhythmia, cardiac arrest, and SD with OM treatment, especially in patients with severely reduced LVEF. These findings require prospective validation in the ongoing COMET-HF trial.
Authors
- Punag Divanji (ORCID: https://orcid.org/0000-0003-2868-4144)
- Stephen B. Heitner (ORCID: https://orcid.org/0000-0003-2189-1474)
- Stuart Kupfer (ORCID: https://orcid.org/0000-0002-5469-1287)
- Alberto Foà
- Fady I. Malik
- Rafael Díaz
- John J V McMurray
- J R Teerlink
- M Metra
- Scott D Solomon
- Muthiah Vaduganathan
- Brian L Claggett
- G Michael Felker
Institutions
- Brigham and Women's Hospital (US)
- San Francisco VA Medical Center (US)
- Harvard University (US)
- Clinical Research Institute (US)
- Surgical Specialties (Canada) (CA)
- Azienda USL di Bologna (IT)
- Instituto Cardiovascular de Rosario (AR)
- Duke University Hospital (US)
- University of Glasgow (GB)
- University of Brescia (IT)
- Cytel (United States) (US)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2026-02-11
- DOI
- https://doi.org/10.1093/ejhf/xuag023
- Primary Topic
- Cardiac pacing and defibrillation studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00